首页> 外文期刊>Expert opinion on therapeutic targets >Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging
【24h】

Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging

机译:针对GSK3信号作为神经变性疾病和老化的潜在治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Glycogen synthase kinase 3 (GSK3) is at the center of cellular signaling and controls various aspects of brain functions, including development of the nervous system, neuronal plasticity and onset of neurodegenerative disorders. Areas covered: In this review, recent efforts in elucidating the roles of GSK3 in neuronal plasticity and development of brain pathologies; Alzheimer's and Parkinson's disease, schizophrenia, and age-related neurodegeneration are described. The effect of microglia and astrocytes on development of the pathological states is also discussed. Expert opinion: GSK3pS and its signaling pathway partners hold great promise as therapeutic target(s) for a multitude of neurological disorders. Activity of the kinase is often elevated in brain disorders. However, due to the wide range of GSK3 cellular targets, global inhibition of the kinase leads to severe side-effects and GSK3 inhibitors rarely reach Phase-2 clinical trials. Thus, a selective modulation of a specific cellular pool of GSK3 or specific down- or upstream partners of the kinase might provide more efficient anti-neurodegenerative therapies.
机译:简介:糖原合酶激酶3(GSK3)位于细胞信号传导的中心,并控制脑功能的各个方面,包括神经系统的发育,神经元塑性和神经变性障碍的发作。所涵盖的地区:在本报告中,最近努力阐明GSK3在神经元可塑性和大脑病理发展中的作用;描述了Alzheimer和帕金森病,精神分裂症和与年龄相关的神经变性。还讨论了微胶质细胞和星形胶质细胞对病理国家发展的影响。专家意见:GSK3PS及其信号通路合作伙伴作为众多神经系统疾病的治疗目标保持巨大的希望。激酶的活性通常在脑疾病中升高。然而,由于GSK3细胞靶标的广泛,全局抑制激酶导致严重的副作用,GSK3抑制剂很少达到2阶段-2临床试验。因此,对激酶的GSK3或特异性下游或上游合作伙伴的特异性细胞池的选择性调节可以提供更有效的抗神经变性疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号